Soligenix (NASDAQ:SNGX – Get Free Report) and Zura Bio (NASDAQ:ZURA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.
Earnings & Valuation
This table compares Soligenix and Zura Bio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Soligenix | $120,000.00 | 46.93 | -$11.08 million | ($0.98) | -0.39 |
| Zura Bio | N/A | N/A | -$99.35 million | ($1.13) | -4.90 |
Profitability
This table compares Soligenix and Zura Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Soligenix | N/A | -180.25% | -107.46% |
| Zura Bio | N/A | -56.13% | -50.15% |
Risk and Volatility
Soligenix has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and target prices for Soligenix and Zura Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Soligenix | 1 | 0 | 0 | 0 | 1.00 |
| Zura Bio | 1 | 0 | 5 | 1 | 2.86 |
Zura Bio has a consensus price target of $17.00, indicating a potential upside of 206.86%. Given Zura Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Zura Bio is more favorable than Soligenix.
Insider & Institutional Ownership
3.6% of Soligenix shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 1.9% of Soligenix shares are owned by company insiders. Comparatively, 12.4% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Zura Bio beats Soligenix on 8 of the 13 factors compared between the two stocks.
About Soligenix
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.
